Atea (AVIR) Q2 Loss Narrows 8%
Atea Pharmaceuticals (NASDAQ:AVIR), a biopharmaceutical company focused on developing therapies for viral diseases, reported its second quarter 2025 results on August 7, 2025. The release highlighted improving cost controls and continued advancement in its Phase 3 clinical program for hepatitis C, but also underscored ongoing risks from late-stage competition and a lack of near-term revenue. The company reported a GAAP net loss per share of $0.44 for Q2 2025, better than both the consensus estimate of a GAAP loss of $0.42 per share for Q2 2025 and the prior year's GAAP net loss per share of $0.48 for Q2 2024. As expected, no revenue was reported since the company is still in clinical development. Overall, the period showed Atea controlling costs and maintaining strong liquidity, while progressing its lead product, but with key questions remaining on timing, competitive strength, and commercial strategy.
Source: Analyst estimates for the quarter provided by FactSet.
Atea Pharmaceuticals is a clinical-stage biotechnology company with a primary focus on treating hepatitis C virus (HCV) infection. Its main asset is a combination therapy using two antiviral compounds: bemnifosbuvir, a nucleotide polymerase inhibitor, and ruzasvir, an NS5A inhibitor. Both are designed to block the virus's ability to replicate in the body.
Source Fool.com
